Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

Abstract

1 Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63: 243–5. 2 Alexandre K, Reveillon-Istin M, Fabre R et al. Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods. J Antimicrob Chemother 2018; 73: 1848–53. 3 Alexandre K, Fantin B. Pharmacokinetics and pharmacodynamics of temocillin. Clin Pharmacokinet 2018; 57: 287–96. 4 Delattre IK, Taccone FS, Jacobs F et al. Optimizing b-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther 2017; 15: 677–88. 5 Tam VH, Chang KT, Zhou J et al. Determining b-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother 2017; 72: 1421–8. 6 Laterre PF, Wittebole X, Van de Velde S et al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother 2015; 70: 891–8. 7 Ngougni Pokem P, Miranda Bastos AC, Tulkens PM et al. Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. Clin Biochem 2015; 48: 542–5. 8 Caglar V, Kumral B, Uygur R et al. Study of volume, weight and size of normal pancreas, spleen and kidney in adults autopsies. FMAR 2014; 2: 63–9. 9 Deitchman AN, Singh RSP, Derendorf H. Nonlinear protein binding: not what you think. J Pharm Sci 2018; 107: 1754–60. J Antimicrob Chemother 2019; 74: 1461–1463 doi:10.1093/jac/dkz009 Advance Access publication 5 February 2019